Key result
Cardiovascular-kidney-metabolic syndrome stage 4 was associated with a higher 15-year cumulative incidence of cardiovascular mortality compared to stage 0 (15.2% vs 5.5%; risk difference 9.6%).
Why the study?
It was necessary to evaluate the prognostic implications of cardiovascular-kidney-metabolic (CKM) syndrome staging to inform clinical practice by defining mortality risk and restricted mean survival time.
Does higher cardiovascular-kidney-metabolic (CKM) syndrome stage increase the risk of cardiovascular mortality in community-dwelling US adults?
Cohort (n=50,678)
Yes
Does higher cardiovascular-kidney-metabolic (CKM) syndrome stage increase the risk of cardiovascular mortality in community-dwelling US adults?
Effect estimate: Absolute risk difference 9.6% (95% CI 5.6-13.6)
Absolute Event Rate: 15.2% vs 5.5%
Higher stages of cardiovascular-kidney-metabolic (CKM) syndrome are associated with a graded increase in cardiovascular mortality, validating the prognostic utility of the AHA CKM staging system.
Supports CKM staging for mortality risk stratification in US adults; extends AHA system validation but leaves causal effects open.
Key Points Cardiovascular–kidney–metabolic (CKM) syndrome stages 1–4 were associated with a graded risk of cardiovascular mortality in a nationally representative sample of US adults. Risk was similar between stages 0 and 1, suggesting that stage 1 represents a prime opportunity for prevention and risk mitigation. CKM staging is specific to cardiovascular mortality, given lack of a strong association with either noncardiovascular or cancer mortality. Background It is imperative to critically evaluate the prognostic implications of cardiovascular–kidney–metabolic (CKM) syndrome staging to inform clinical practice. The primary aims of this study were to define the risk of mortality associated with each CKM syndrome stage and to determine the corresponding restricted mean survival time over a 15-year period. Methods This was a longitudinal study of 50,678 community-dwelling US adults aged 20 years and older with baseline data for CKM stage determination participating in the 1999–2018 National Health and Nutrition Examination Survey. CKM stages were defined according to the American Heart Association presidential advisory. Fifteen-year adjusted cumulative incidences of cardiovascular mortality were calculated for each stage from confounder-adjusted survival curves using the G-formula. Results Over a median 9.5-year follow-up, 2564 participants experienced cardiovascular death. The 15-year adjusted cumulative incidences of cardiovascular mortality were stage 0, 5.5% (95% confidence interval [CI], 1.8 to 9.3); stage 1, 5.7% (95% CI, 3.2 to 8.2); stage 2, 7.9% (95% CI, 6.8 to 9.1); stage 3, 8.7% (95% CI, 6.7 to 10.8); and stage 4, 15.2% (95% CI, 13.6 to 16.8). The absolute risk difference between CKM stage 4 and stage 0 at 15 years was 9.6% (95% CI, 5.6 to 13.6). The survival difference between CKM stage 0 and stage 4 at 15 years was 8.1 (95% CI, 8.0 to 8.2) months. Conclusions Our findings reveal a graded risk of cardiovascular mortality associated with higher CKM syndrome stage.
No takes yet. Share an insight, caveat, or question.
Claudel et al. (2025) conducted a cohort in Cardiovascular-kidney-metabolic (CKM) syndrome (n=50,678). Cardiovascular-kidney-metabolic (CKM) syndrome stage 4 vs. CKM syndrome stage 0 was evaluated on 15-year adjusted cumulative incidence of cardiovascular mortality (Absolute risk difference 9.6%, 95% CI 5.6-13.6). Cardiovascular-kidney-metabolic syndrome stage 4 was associated with a higher 15-year cumulative incidence of cardiovascular mortality compared to stage 0 (15.2% vs 5.5%; risk difference 9.6%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: